Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Livmoniplimab - AbbVie

Drug Profile

Livmoniplimab - AbbVie

Alternative Names: ABBV-151; ARGX-115; MHG-8

Latest Information Update: 07 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Catholic University of Louvain; Ludwig Institute for Cancer Research
  • Developer AbbVie
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer
  • Phase I Solid tumours

Most Recent Events

  • 01 Feb 2024 Abbvie plans a phase II/III LIVIGNO-4 trial for Non-small cell lung cancer (Combination therapy, First-line therapy, Metastatic disease) (IV) in April 2024 (NCT06236438)
  • 25 Jan 2024 Efficacy, adverse event and pharmacokinetics data from phase I trial in Solid tumours presented at the 2024 Genitourinary Cancers Symposium (ASCO-GeCS-2024)
  • 03 Nov 2023 AbbVie plans a phase II/III LIVIGNO-2 trial for Liver cancer (Late-stage disease, Metastatic disease, Combination therapy, Inoperable/Unresectable, First line therapy) (IV) (NCT06109272)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top